Pub Date : 2026-01-01Epub Date: 2026-01-29DOI: 10.1016/j.cccb.2026.100531
Anna M. Streiber , Carmen Kuenen , Stanley D.T. Pham , Julia Neitzel , Daniel Bos , Jeroen C.W. Siero , Jaco J.M. Zwanenburg , Nikki Dieleman , Geert Jan Biessels , Meike W. Vernooij
Background
Intracranial arteriosclerosis may impair downstream cerebrovascular function, but the underlying mechanisms remain unclear. Using 7T MRI, we investigate the association between intracranial arteriosclerosis and cerebrovascular function in the middle cerebral artery (MCA) and in downstream small perforating arteries.
Methods
We included 195 Rotterdam Study participants (43.6% female, average age 70.8 years (± 4.52 years)) who previously underwent a non-contrast CT on which we measured intracranial carotid artery calcification (ICAC) and vertebral artery calcification (VAC) as hallmarks of intracranial arteriosclerosis. Participants underwent a 7T brain MRI to assess blood flow velocity and pulsatility in the MCA and small perforating arteries as well as whole-brain cerebrovascular reactivity (CVR). We assessed the relationship between intracranial arteriosclerosis and vessel function using linear regression and linear mixed models.
Results
ICAC and VAC presence and burden were associated with higher pulsatility but not blood flow velocity in the MCA (e.g. βICAC presence: 0.07 [95% Confidence interval: 0.02, 0.13]). There was no statistically significant association with CVR, pulsatility, and blood flow velocity in the small perforating arteries.
Conclusions
In this cohort, intracranial arterial calcification was associated with increased MCA pulsatility, suggesting a localized impact on cerebrovascular hemodynamics. Associations with CVR and perforating artery flow velocity and pulsatility did not reach statistical significance. Thus, larger studies are needed to determine whether subtle effects exist.
{"title":"Intracranial arterial calcification and cerebrovascular function in the general aging population – A 7T MRI Study","authors":"Anna M. Streiber , Carmen Kuenen , Stanley D.T. Pham , Julia Neitzel , Daniel Bos , Jeroen C.W. Siero , Jaco J.M. Zwanenburg , Nikki Dieleman , Geert Jan Biessels , Meike W. Vernooij","doi":"10.1016/j.cccb.2026.100531","DOIUrl":"10.1016/j.cccb.2026.100531","url":null,"abstract":"<div><h3>Background</h3><div>Intracranial arteriosclerosis may impair downstream cerebrovascular function, but the underlying mechanisms remain unclear. Using 7T MRI, we investigate the association between intracranial arteriosclerosis and cerebrovascular function in the middle cerebral artery (MCA) and in downstream small perforating arteries.</div></div><div><h3>Methods</h3><div>We included 195 Rotterdam Study participants (43.6% female, average age 70.8 years (± 4.52 years)) who previously underwent a non-contrast CT on which we measured intracranial carotid artery calcification (ICAC) and vertebral artery calcification (VAC) as hallmarks of intracranial arteriosclerosis. Participants underwent a 7T brain MRI to assess blood flow velocity and pulsatility in the MCA and small perforating arteries as well as whole-brain cerebrovascular reactivity (CVR). We assessed the relationship between intracranial arteriosclerosis and vessel function using linear regression and linear mixed models.</div></div><div><h3>Results</h3><div>ICAC and VAC presence and burden were associated with higher pulsatility but not blood flow velocity in the MCA (e.g. β<sub>ICAC presence</sub>: 0.07 [95% Confidence interval: 0.02, 0.13]). There was no statistically significant association with CVR, pulsatility, and blood flow velocity in the small perforating arteries.</div></div><div><h3>Conclusions</h3><div>In this cohort, intracranial arterial calcification was associated with increased MCA pulsatility, suggesting a localized impact on cerebrovascular hemodynamics. Associations with CVR and perforating artery flow velocity and pulsatility did not reach statistical significance. Thus, larger studies are needed to determine whether subtle effects exist.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"10 ","pages":"Article 100531"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-02-28DOI: 10.1016/j.cccb.2026.100535
Erik J. Timmermans , Esther E. Bron , Michiel L. Bots , Anna E. Leeuwis , Justine E.F. Moonen , Frank J. Wolters , Geert Jan Biessels , Ilonca Vaartjes , Heart-Brain Connection Consortium
There is increasing evidence of an inverse relationship between air pollution and cognitive functioning. Yet, the biological mechanisms underlying this relationship remain underexplored in healthy and vulnerable populations. This study examined cross-sectional and longitudinal associations between air pollution and global cognitive functioning in individuals without or with heart failure, carotid occlusive disease, or vascular cognitive impairment. We also assessed whether the cross-sectional associations were mediated by white matter hyperintensities (WMH), total brain volume (TBV), and cerebral blood flow (CBF). The cross-sectional and longitudinal analyses included data from 341 and 180 Heart-Brain Study participants, respectively. Cognitive functioning was measured using neuropsychological tests at baseline and two-year follow-up. Brain Magnetic Resonance Imaging provided WMH and TBV in mL, and CBF in mL/100g/min. WMH and TBV were divided by total intracranial volume. Annual average outdoor concentrations of particulate matter with diameters <2.5 µm and <10.0 µm, and nitrogen dioxide in µg/m3 in residential six-digit postal code areas were linked to participants at baseline. Adjusted multi-level regression analyses showed no significant cross-sectional or longitudinal associations between air pollution and global cognitive functioning. The associations between air pollutants and global cognitive functioning were not significantly mediated by WMH, TBV, and CBF. In this study, air pollution was not associated with global cognitive functioning or brain health indicators in healthy individuals and those with cardiovascular disorders along the heart-brain axis. Larger studies with longer follow-up periods are warranted to extend the present findings and to further elucidate potential associations between air pollution, cognition, and the underlying biological mechanisms.
{"title":"Air pollution in relation to brain health indicators and global cognitive functioning in people with cardiovascular disorders along the heart-brain axis","authors":"Erik J. Timmermans , Esther E. Bron , Michiel L. Bots , Anna E. Leeuwis , Justine E.F. Moonen , Frank J. Wolters , Geert Jan Biessels , Ilonca Vaartjes , Heart-Brain Connection Consortium","doi":"10.1016/j.cccb.2026.100535","DOIUrl":"10.1016/j.cccb.2026.100535","url":null,"abstract":"<div><div>There is increasing evidence of an inverse relationship between air pollution and cognitive functioning. Yet, the biological mechanisms underlying this relationship remain underexplored in healthy and vulnerable populations. This study examined cross-sectional and longitudinal associations between air pollution and global cognitive functioning in individuals without or with heart failure, carotid occlusive disease, or vascular cognitive impairment. We also assessed whether the cross-sectional associations were mediated by white matter hyperintensities (WMH), total brain volume (TBV), and cerebral blood flow (CBF). The cross-sectional and longitudinal analyses included data from 341 and 180 Heart-Brain Study participants, respectively. Cognitive functioning was measured using neuropsychological tests at baseline and two-year follow-up. Brain Magnetic Resonance Imaging provided WMH and TBV in mL, and CBF in mL/100g/min. WMH and TBV were divided by total intracranial volume. Annual average outdoor concentrations of particulate matter with diameters <2.5 µm and <10.0 µm, and nitrogen dioxide in µg/m<sup>3</sup> in residential six-digit postal code areas were linked to participants at baseline. Adjusted multi-level regression analyses showed no significant cross-sectional or longitudinal associations between air pollution and global cognitive functioning. The associations between air pollutants and global cognitive functioning were not significantly mediated by WMH, TBV, and CBF. In this study, air pollution was not associated with global cognitive functioning or brain health indicators in healthy individuals and those with cardiovascular disorders along the heart-brain axis. Larger studies with longer follow-up periods are warranted to extend the present findings and to further elucidate potential associations between air pollution, cognition, and the underlying biological mechanisms.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"10 ","pages":"Article 100535"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-12-05DOI: 10.1016/j.cccb.2024.100372
Katie Harris , Jessica Gong , Stephen MacMahon , Ying Xu , Sultana Shajahan , Stephen Harrap , Neil Poulter , Michel Marre , Pavel Hamet , Giuseppe Mancia , Craig Anderson , Mark Woodward , John Chalmers
Background and aims
Accumulating evidence indicates that reducing high blood pressure (BP) prevents dementia and mild cognitive impairment (MCI). Furthermore, although diabetes is a risk factor for dementia and MCI, there is uncertainty of the effect of intensive glucose control on these endpoints. This study aimed to determine the effects of BP-lowering (vs placebo) and intensive glucose-lowering (vs standard control) treatments according to baseline cognition and other characteristics on dementia and cognitive decline (CD) in people with type 2 diabetes mellitus (T2DM).
Methods
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial involved 11,140 individuals with T2DM. The effects of BP-lowering and intensive glucose-lowering treatments were explored in subgroups of baseline Mini-Mental State Examination (MMSE), categorised as cognitively normal (scores ≥28) and cognitive impairment (scores <28). The primary outcome was a composite of dementia/CD that accounted for the competing risk of death. Multinomial regression models, adjusted for common cardiovascular risk factors, were used to estimate odds ratios (OR) with 95 % confidence intervals (CI) of the effects of the treatments on dementia/CD. Homogeneity of effects by subgroups were evaluated using interaction terms in the models. A two-sided p value <0.05 was regarded as statistically significant.
Results
BP-lowering treatment (vs. placebo) was associated with a lower odds of dementia/CD in participants with cognitive impairment (OR 0.76, 95 % CI (0.59–0.99)) but not in those cognitively normal (OR 1.05, 95 % CI (0.92–1.21); p for interaction 0.03). Those with a history of cardio-renal-metabolic syndrome did not experience a benefit of active BP lowering treatment compared with placebo on dementia/CD. There were no further subgroup effects of BP-lowering treatment. The effect of intensive glucose lowering (vs standard control) on the odds of dementia/CD did not vary by baseline cognition subgroup. However, it did vary by level of blood glucose at baseline (<7.9 mmol/L OR 1.12, 95 % CI (0.96–1.30) vs ≥ 7.9 mmol/L 0.87 (0.75–1.00); p for interaction 0.02) and duration of T2DM (<10 years OR 0.92 (0.81–1.05) vs ≥10 years 1.16 (0.97–1.38); p for interaction 0.04).
Conclusions
This study suggests greater effects of BP-lowering treatment in those with early loss of cognitive function than in those cognitively normal. There were also differential effects of intensive glucose-lowering on dementia and CD according to levels of blood glucose and duration of diabetes in people with T2DM.
Clinical trial registration
ADVANCE is registered with ClinicalTrials.gov: number NCT00145925
背景和目的:越来越多的证据表明,降低高血压(BP)可以预防痴呆和轻度认知障碍(MCI)。此外,虽然糖尿病是痴呆和轻度认知障碍的危险因素,但强化血糖控制对这些终点的影响尚不确定。本研究旨在根据基线认知和其他特征确定降压(相对于安慰剂)和强化降糖(相对于标准对照)治疗对2型糖尿病(T2DM)患者痴呆和认知能力下降(CD)的影响。方法:在糖尿病和血管疾病中的作用:Preterax和Diamicron改良释放控制评价(ADVANCE)试验纳入11,140例T2DM患者。在基线迷你精神状态检查(MMSE)的亚组中,研究了降压和强化降糖治疗的效果,分为认知正常(评分≥28)和认知障碍(评分结果:降压治疗(与安慰剂相比)与认知障碍参与者的痴呆/CD发生率较低相关(OR 0.76, 95% CI(0.59-0.99)),但与认知正常参与者无关(OR 1.05, 95% CI (0.92-1.21);P为相互作用0.03)。与安慰剂相比,那些有心肾代谢综合征病史的患者在痴呆/CD方面没有得到主动降压治疗的益处。降压治疗没有进一步的亚组效应。强化降糖(与标准对照)对痴呆/CD几率的影响在基线认知亚组中没有变化。然而,它确实因基线血糖水平而异(结论:这项研究表明,与认知功能正常的人相比,早期认知功能丧失的人降压治疗的效果更大。根据2型糖尿病患者的血糖水平和糖尿病病程,强化降糖对痴呆和CD的影响也存在差异。临床试验注册:ADVANCE在ClinicalTrials.gov注册:编号NCT00145925。
{"title":"Effect of randomised blood pressure lowering treatment and intensive glucose control on dementia and cognitive decline according to baseline cognitive function and other subpopulations of individuals with type 2 diabetes: Results from the ADVANCE trial","authors":"Katie Harris , Jessica Gong , Stephen MacMahon , Ying Xu , Sultana Shajahan , Stephen Harrap , Neil Poulter , Michel Marre , Pavel Hamet , Giuseppe Mancia , Craig Anderson , Mark Woodward , John Chalmers","doi":"10.1016/j.cccb.2024.100372","DOIUrl":"10.1016/j.cccb.2024.100372","url":null,"abstract":"<div><h3>Background and aims</h3><div>Accumulating evidence indicates that reducing high blood pressure (BP) prevents dementia and mild cognitive impairment (MCI). Furthermore, although diabetes is a risk factor for dementia and MCI, there is uncertainty of the effect of intensive glucose control on these endpoints. This study aimed to determine the effects of BP-lowering (vs placebo) and intensive glucose-lowering (vs standard control) treatments according to baseline cognition and other characteristics on dementia and cognitive decline (CD) in people with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial involved 11,140 individuals with T2DM. The effects of BP-lowering and intensive glucose-lowering treatments were explored in subgroups of baseline Mini-Mental State Examination (MMSE), categorised as cognitively normal (scores ≥28) and cognitive impairment (scores <28). The primary outcome was a composite of dementia/CD that accounted for the competing risk of death. Multinomial regression models, adjusted for common cardiovascular risk factors, were used to estimate odds ratios (OR) with 95 % confidence intervals (CI) of the effects of the treatments on dementia/CD. Homogeneity of effects by subgroups were evaluated using interaction terms in the models. A two-sided p value <0.05 was regarded as statistically significant.</div></div><div><h3>Results</h3><div>BP-lowering treatment (vs. placebo) was associated with a lower odds of dementia/CD in participants with cognitive impairment (OR 0.76, 95 % CI (0.59–0.99)) but not in those cognitively normal (OR 1.05, 95 % CI (0.92–1.21); p for interaction 0.03). Those with a history of cardio-renal-metabolic syndrome did not experience a benefit of active BP lowering treatment compared with placebo on dementia/CD. There were no further subgroup effects of BP-lowering treatment. The effect of intensive glucose lowering (vs standard control) on the odds of dementia/CD did not vary by baseline cognition subgroup. However, it did vary by level of blood glucose at baseline (<7.9 mmol/L OR 1.12, 95 % CI (0.96–1.30) vs ≥ 7.9 mmol/L 0.87 (0.75–1.00); p for interaction 0.02) and duration of T2DM (<10 years OR 0.92 (0.81–1.05) vs ≥10 years 1.16 (0.97–1.38); p for interaction 0.04).</div></div><div><h3>Conclusions</h3><div>This study suggests greater effects of BP-lowering treatment in those with early loss of cognitive function than in those cognitively normal. There were also differential effects of intensive glucose-lowering on dementia and CD according to levels of blood glucose and duration of diabetes in people with T2DM.</div></div><div><h3>Clinical trial registration</h3><div>ADVANCE is registered with ClinicalTrials.gov: number NCT00145925</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"8 ","pages":"Article 100372"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100419
Alexandra Morozova , Maria del C. Valdés Hernández , Roberto Duarte Coello , Heather Whalley , Andrew McIntosh , Anca-Larisa Sandu Giuraniuc , Gordon D. Waiter , Christopher J McNeil , Douglas Steele , Joanna M. Wardlaw
Introduction
Stress, depressive symptoms, cardiovascular health, and physical strength are well-recognised factors contributing to microcirculatory changes in the brain, accentuating the multifactorial nature of these alterations. MRI-detectable brain perivascular spaces (PVS) have been proposed as neuroimaging markers reflecting microcirculatory dynamics. However, it remains unclear whether perivascular morphology is affected by these neuropsychiatric and physiological determinants, and which specific morphometric features are influenced by familial factors beyond established overall genetic contributions. Therefore, our study aims to investigate the associations between neuropsychiatric factors – hair cortisol, Quick Inventory of Depressive Symptomatology scale score, and hand grip strength – and PVS characteristics in a healthy aging population. In addition, it seeks to investigate the potential influence of familial factors on PVS characteristics through first-degree relatives.
Methods
We used the Stratifying Depression and Resilience Longitudinally (STRADL) family-based cohort to assess the association between these factors, familial influences, and PVS characteristics. Using an automated segmentation method on brain magnetic resonance images, we generated perivascular space volume, count, density (i.e., count per unit volume), and median length in the centrum semiovale (CSO) and the basal ganglia (BG) of 1183 participants, including 324 subjects with first-degree relatives within the cohort. The statistical analyses were conducted using Linear Mixed Effects Models built for each PVS measurement.
Results
Significant associations were identified between increasing PVS burden, advancing age and current depressive symptoms in both the BG and the CSO regions. Increased PVS burden in the CSO was associated with higher hair cortisol and weaker hand grip strength. Familial factors were significant in determining PVS volume and median length in the CSO, with age being a substantial contributor.
Conclusions
Chronic stress exposure and physical strength are reflected in the PVS morphology of the CSO, whereas depressive symptomatology affects both the BG and the CSO regions. Familial effects on CSO PVS volume and length were observed, contributing to our understanding of potential genetic and environmental influences on PVS morphology.
The regional variability in PVS burden provides insights into differences in the pathophysiology of perivascular clearance across brain regions, suggesting that specific changes in PVS characteristics may depend on the nature of influencing factors.
{"title":"Morphometric Features of Brain Perivascular Spaces and Their Neuropsychiatric and Familial Associations","authors":"Alexandra Morozova , Maria del C. Valdés Hernández , Roberto Duarte Coello , Heather Whalley , Andrew McIntosh , Anca-Larisa Sandu Giuraniuc , Gordon D. Waiter , Christopher J McNeil , Douglas Steele , Joanna M. Wardlaw","doi":"10.1016/j.cccb.2025.100419","DOIUrl":"10.1016/j.cccb.2025.100419","url":null,"abstract":"<div><h3>Introduction</h3><div>Stress, depressive symptoms, cardiovascular health, and physical strength are well-recognised factors contributing to microcirculatory changes in the brain, accentuating the multifactorial nature of these alterations. MRI-detectable brain perivascular spaces (PVS) have been proposed as neuroimaging markers reflecting microcirculatory dynamics. However, it remains unclear whether perivascular morphology is affected by these neuropsychiatric and physiological determinants, and which specific morphometric features are influenced by familial factors beyond established overall genetic contributions. Therefore, our study aims to investigate the associations between neuropsychiatric factors – hair cortisol, Quick Inventory of Depressive Symptomatology scale score, and hand grip strength – and PVS characteristics in a healthy aging population. In addition, it seeks to investigate the potential influence of familial factors on PVS characteristics through first-degree relatives.</div></div><div><h3>Methods</h3><div>We used the Stratifying Depression and Resilience Longitudinally (STRADL) family-based cohort to assess the association between these factors, familial influences, and PVS characteristics. Using an automated segmentation method on brain magnetic resonance images, we generated perivascular space volume, count, density (i.e., count per unit volume), and median length in the centrum semiovale (CSO) and the basal ganglia (BG) of 1183 participants, including 324 subjects with first-degree relatives within the cohort. The statistical analyses were conducted using Linear Mixed Effects Models built for each PVS measurement.</div></div><div><h3>Results</h3><div>Significant associations were identified between increasing PVS burden, advancing age and current depressive symptoms in both the BG and the CSO regions. Increased PVS burden in the CSO was associated with higher hair cortisol and weaker hand grip strength. Familial factors were significant in determining PVS volume and median length in the CSO, with age being a substantial contributor.</div></div><div><h3>Conclusions</h3><div>Chronic stress exposure and physical strength are reflected in the PVS morphology of the CSO, whereas depressive symptomatology affects both the BG and the CSO regions. Familial effects on CSO PVS volume and length were observed, contributing to our understanding of potential genetic and environmental influences on PVS morphology.</div><div>The regional variability in PVS burden provides insights into differences in the pathophysiology of perivascular clearance across brain regions, suggesting that specific changes in PVS characteristics may depend on the nature of influencing factors.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100419"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100475
Christian Crouzet , Jihua Liu , Bernard Choi , David H Cribbs
Introduction
Introduction: Three Alzheimer disease-modifying anti-Aβ antibodies (aducanumab, lecanemab, and donanemab) have been approved since 2021. However, Amyloid Related Imaging Abnormalities (ARIAs) remain problematic, with rare serious adverse events and deaths linked to amyloid-immunotherapy (six deaths from macro- hemorrhages and eight from severe inflammatory ARIA-E). Investigating the underlying adverse cerebrovascular responses to passive anti-Aβ immunotherapy is critical to improve patient safety. The mechanisms driving these potentially fatal events remain poorly understood, necessitating robust preclinical models. This study aimed to investigate ARIAs following Ab immunotherapy in 5XFAD mice with different genetic backgrounds to develop better models for studying adverse cerebrovascular responses.
Methods
Methods: Study 1: Ten 8-10-month-old 5XFAD.WSB.EiJ female mice received single IP injections of 3D6 anti-Aβ antibody (7.0 mg/kg), and five received IgG2a(k) isotype control (BioXCell). The 3D6.IgG2a monoclonal (from Dr. Ron Demattos, Eli Lilly) offers strong FcgR-mediated response with weak inhibitory activity and complement activation capability. Blood vessels were labeled with Lectin-Dylight-649 via retro-orbital injection.
Amyloid plaques and CAA were labeled with Amylo-glo RTD and H&E staining detected vasculitis/angiitis. Study 2: Earlier time points (12, 24, 36 hours) compared 5XFAD.WSB.EiJ versus 5XFAD.C57B/6J responses to 3D6.IgG2a (5 mice/timepoint). Evans blue assessed blood-brain barrier integrity loss.
Results
Results: Study 1 was designed for 8 weeks with weekly 3D6.IgG2a injections, but was aborted after the first injection when 7/10 mice died within 36 hours. The remaining 3 mice were perfused to salvage data. All 3D6.IgG2a-treated brains showed surface macro- hemorrhages (Figure 1), while the IgG2a controls had no visible bleeds. Study 2 revealed striking strain differences: 5XFAD.C57B/6J mice were resistant to 3D6.IgG2a at all timepoints, while 5XFAD.WSB.EiJ brains showed modest surface lesions at 12 hours, prominent hemorrhages by 24 hours, and distress signs by 27 hours.
Conclusions
Conclusions: Comparing anti-Ab immunotherapy responses between 5XFAD.C57B/6J versus 5XFAD.WSB.EiJ mice provide insights into aging, amyloid plaque, and CAA contributions to ARIA development. The 3D6 antibody was chosen because its humanized version (bapineuzumab) previously reduced Aβ pathology while inducing ARIA-E and ARIA-H in patients. ARIA-like responses in 5XFAD.WSB.EiJ mice may provide a valuable model for investigating causes of serious adverse events in human amyloid immunotherapy patients.
自2021年以来,三种阿尔茨海默病修饰抗a β抗体(aducanumab, lecanemab和donanemab)已获批。然而,淀粉样蛋白相关成像异常(ARIAs)仍然存在问题,与淀粉样蛋白免疫治疗相关的罕见严重不良事件和死亡(6例死于大出血,8例死于严重炎症性ARIAs - e)。研究被动抗a β免疫治疗潜在的不良脑血管反应对提高患者安全性至关重要。驱动这些潜在致命事件的机制仍然知之甚少,需要健全的临床前模型。本研究旨在研究不同遗传背景的5XFAD小鼠Ab免疫治疗后的ARIAs,为研究脑血管不良反应建立更好的模型。方法:研究1:10例8 ~ 10月龄5XFAD.WSB。EiJ雌性小鼠单次IP注射3D6抗a β抗体(7.0 mg/kg), 5只接受IgG2a(k)同型对照(BioXCell)。3 d6。IgG2a单克隆(来自Dr. Ron Demattos, Eli Lilly)具有较强的fcgr介导应答,但具有较弱的抑制活性和补体激活能力。血管经眶后注射凝集素- dylight -649标记。淀粉样斑块和CAA用Amylo-glo RTD标记,H&;E染色检测血管炎/脉管炎。研究2:与5XFAD.WSB相比,更早的时间点(12,24,36小时)。EiJ和5XFAD。C57B/6J对3D6的响应IgG2a(5只小鼠/时间点)。埃文斯蓝评估血脑屏障完整性损失。结果:研究1设计为8周,每周3D6。但在第一次注射后流产,7/10的小鼠在36小时内死亡。其余3只小鼠灌注保存数据。所有3 d6。IgG2a处理的大脑显示表面大出血(图1),而IgG2a对照组没有明显出血。研究2显示了显著的菌株差异:5XFAD。C57B/6J小鼠3D6耐药。在所有时间点IgG2a,而5XFAD.WSB。12小时时,EiJ脑表面出现轻度损伤,24小时时出现明显出血,27小时时出现窘迫症状。结论:比较5XFAD患者抗ab免疫治疗反应。C57B/6J与5XFAD.WSB。EiJ小鼠提供了对衰老、淀粉样斑块和CAA对ARIA发展的贡献的见解。选择3D6抗体是因为其人源化版本(bapineuzumab)先前在诱导ARIA-E和ARIA-H的同时降低了Aβ病理。5XFAD.WSB中的类aria响应。EiJ小鼠可能为研究人类淀粉样蛋白免疫治疗患者严重不良事件的原因提供有价值的模型。
{"title":"A Novel Mouse Model for Investigating ARIAs in Response to Anti-Abeta Immunotherapy","authors":"Christian Crouzet , Jihua Liu , Bernard Choi , David H Cribbs","doi":"10.1016/j.cccb.2025.100475","DOIUrl":"10.1016/j.cccb.2025.100475","url":null,"abstract":"<div><h3>Introduction</h3><div>Introduction: Three Alzheimer disease-modifying anti-Aβ antibodies (aducanumab, lecanemab, and donanemab) have been approved since 2021. However, Amyloid Related Imaging Abnormalities (ARIAs) remain problematic, with rare serious adverse events and deaths linked to amyloid-immunotherapy (six deaths from macro- hemorrhages and eight from severe inflammatory ARIA-E). Investigating the underlying adverse cerebrovascular responses to passive anti-Aβ immunotherapy is critical to improve patient safety. The mechanisms driving these potentially fatal events remain poorly understood, necessitating robust preclinical models. This study aimed to investigate ARIAs following Ab immunotherapy in 5XFAD mice with different genetic backgrounds to develop better models for studying adverse cerebrovascular responses.</div></div><div><h3>Methods</h3><div>Methods: Study 1: Ten 8-10-month-old 5XFAD.WSB.EiJ female mice received single IP injections of 3D6 anti-Aβ antibody (7.0 mg/kg), and five received IgG2a(k) isotype control (BioXCell). The 3D6.IgG2a monoclonal (from Dr. Ron Demattos, Eli Lilly) offers strong FcgR-mediated response with weak inhibitory activity and complement activation capability. Blood vessels were labeled with Lectin-Dylight-649 via retro-orbital injection.</div><div>Amyloid plaques and CAA were labeled with Amylo-glo RTD and H&E staining detected vasculitis/angiitis. Study 2: Earlier time points (12, 24, 36 hours) compared 5XFAD.WSB.EiJ versus 5XFAD.C57B/6J responses to 3D6.IgG2a (5 mice/timepoint). Evans blue assessed blood-brain barrier integrity loss.</div></div><div><h3>Results</h3><div>Results: Study 1 was designed for 8 weeks with weekly 3D6.IgG2a injections, but was aborted after the first injection when 7/10 mice died within 36 hours. The remaining 3 mice were perfused to salvage data. All 3D6.IgG2a-treated brains showed surface macro- hemorrhages (Figure 1), while the IgG2a controls had no visible bleeds. Study 2 revealed striking strain differences: 5XFAD.C57B/6J mice were resistant to 3D6.IgG2a at all timepoints, while 5XFAD.WSB.EiJ brains showed modest surface lesions at 12 hours, prominent hemorrhages by 24 hours, and distress signs by 27 hours.</div></div><div><h3>Conclusions</h3><div>Conclusions: Comparing anti-Ab immunotherapy responses between 5XFAD.C57B/6J versus 5XFAD.WSB.EiJ mice provide insights into aging, amyloid plaque, and CAA contributions to ARIA development. The 3D6 antibody was chosen because its humanized version (bapineuzumab) previously reduced Aβ pathology while inducing ARIA-E and ARIA-H in patients. ARIA-like responses in 5XFAD.WSB.EiJ mice may provide a valuable model for investigating causes of serious adverse events in human amyloid immunotherapy patients.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100475"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100468
The VASCOG-2-NP Consortium
Introduction
Harmonization of neuropsychological assessment for vascular cognitive impairment and dementia (VCID) is important for ensuring the highest standards and consistency of diagnosis. A battery proposed in 2006 by the National Institute for Neurological Disorders and Stroke and the Canadian Stroke Network (NINDS-CSN) has received much international support. Considering significant developments in the understanding of small vessel disease and its neuropsychological correlates in VCID, plus a recent increase in remote and computerized assessment methods, an international expert group was established to update this battery and add guidelines.
Methods
Forty-four international experts in neuropsychological assessment from diverse regions were invited to participate. An online Delphi survey (minimum three rounds, ≥ 75% threshold for agreement) was used to achieve consensus on a core test battery based on key cognitive domains that should be assessed for VCID, that is adaptable for telehealth and computerized assessment methods, and for assessment of diverse populations.
Reference points were NINDS-CSN and other relevant published harmonized neuropsychological batteries, aided by literature review of recent developments in VCID.
Results
Three survey rounds included 28-31 participants that agreed on a “Core” assessment battery of neuropsychological tests based on key cognitive domains, and additional guidelines for a more comprehensive test battery, cognitive screening, telehealth and computerized assessment methods, principles for normative standardisation, and the assessment of diverse populations. The key cognitive domains were harmonized with the VASCOG-2-WSO diagnostic criteria for VCID.
Conclusions
The harmonized neuropsychological assessment battery and guidelines for VCID (VASCOG-2-NP) expand upon the NINDS-CSN battery with more comprehensive and flexible assessment of VCID. Harmonized with the VASCOG-2-WSO diagnostic criteria, VASCOG-2-NP could be adopted internationally to further help more consistent neuropsychological evaluations related to VCID. We will compare the VASCOG-2-NP to the NINDS-CSN and other previous batteries for VCID, and discuss future research directions including validation against neuropathological diagnosis of small vessel disease.
{"title":"The VASCOG-2-NP consensus harmonized neuropsychological assessment for Vascular Cognitive Impairment and Dementia: Introduction, validation and future directions","authors":"The VASCOG-2-NP Consortium","doi":"10.1016/j.cccb.2025.100468","DOIUrl":"10.1016/j.cccb.2025.100468","url":null,"abstract":"<div><h3>Introduction</h3><div>Harmonization of neuropsychological assessment for vascular cognitive impairment and dementia (VCID) is important for ensuring the highest standards and consistency of diagnosis. A battery proposed in 2006 by the National Institute for Neurological Disorders and Stroke and the Canadian Stroke Network (NINDS-CSN) has received much international support. Considering significant developments in the understanding of small vessel disease and its neuropsychological correlates in VCID, plus a recent increase in remote and computerized assessment methods, an international expert group was established to update this battery and add guidelines.</div></div><div><h3>Methods</h3><div>Forty-four international experts in neuropsychological assessment from diverse regions were invited to participate. An online Delphi survey (minimum three rounds, ≥ 75% threshold for agreement) was used to achieve consensus on a core test battery based on key cognitive domains that should be assessed for VCID, that is adaptable for telehealth and computerized assessment methods, and for assessment of diverse populations.</div><div>Reference points were NINDS-CSN and other relevant published harmonized neuropsychological batteries, aided by literature review of recent developments in VCID.</div></div><div><h3>Results</h3><div>Three survey rounds included 28-31 participants that agreed on a “Core” assessment battery of neuropsychological tests based on key cognitive domains, and additional guidelines for a more comprehensive test battery, cognitive screening, telehealth and computerized assessment methods, principles for normative standardisation, and the assessment of diverse populations. The key cognitive domains were harmonized with the VASCOG-2-WSO diagnostic criteria for VCID.</div></div><div><h3>Conclusions</h3><div>The harmonized neuropsychological assessment battery and guidelines for VCID (VASCOG-2-NP) expand upon the NINDS-CSN battery with more comprehensive and flexible assessment of VCID. Harmonized with the VASCOG-2-WSO diagnostic criteria, VASCOG-2-NP could be adopted internationally to further help more consistent neuropsychological evaluations related to VCID. We will compare the VASCOG-2-NP to the NINDS-CSN and other previous batteries for VCID, and discuss future research directions including validation against neuropathological diagnosis of small vessel disease.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100468"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100498
Harry Pritchard , Anna Gray , Adam Greenstein , Stuart Allan , Ingo Schiessl , Alexander Clowsley , Christian Soeller , Thea Danby
Introduction
The innate ability of cerebral resistance vessels to maintain constant blood flow during fluctuations in global blood pressures is a tightly controlled process known as autoregulation. This relies on a negative feedback mechanism in vascular smooth muscle cells (SMCs) where calcium sparks released from ryanodine receptors (RyRs) on the sarcoplasmic reticulum (SR) activate large-conductance calcium-activated potassium (BK) channels on the plasma membrane (PM). Efficient activation requires RyRs and BK channels to reside within ∼20nm of each other. Disruption of this nanoscale proximity impairs BK channel activation, compromising vasodilation and blood flow regulation seen during chronic hypertension.
Methods
To investigate RyR-BK spatial coupling, we will utilise DNA-PAINT super- resolution microscopy to image isolated SMCs from wild-type (C57), normotensive (BPN/3), and hypertensive (BPH/2) mice. Confocal microscopy will be used to quantify calcium spark activity and the number of spark sites per cell and electron microscopy (EM) will assess SR- PM contact sites at the ultrastructural level. In-vivo cerebral blood flow (CBF) will be measured using multi-photon microscopy in mice with cranial windows, with vasodilation assessed via CO₂ challenge.
Results
In C57 mice, DNA-PAINT revealed that ∼40% of RyRs were located within 30nm of BK channels, with ∼90% within 100nm, suggesting tight spatial organisation. Calcium imaging showed an average of ∼2 calcium spark sites per isolated SMC, indicating a limited number of functional coupling sites where preliminary EM findings confirmed sparse SR-PM coupling in healthy SMCs. These findings establish a baseline for functional RyR-BK coupling in health. In our previous work (Taylor et al., 2023), BPH/2 mice showed reduced CBF, impaired BK channel activity, and significantly fewer RyR-BK coupling sites compared to BPN/3 controls, indicating a spatial uncoupling during chronic hypertension. Current experiments are extending these analyses in BPH/2 mice using the same imaging modalities to further assess nanoscale changes and functional modifications.
Conclusions
These results suggest RyR-BK coupling is sparse and spatially precise in healthy SMCs, with nanoscale organisation being essential for proper arterial diameter control. Chronic hypertension disrupts this arrangement contributing to impaired autoregulation. Understanding when and how this coupling is lost could help identify new therapeutic strategies to restore cerebrovascular function and prevent cognitive decline.
脑抵抗血管在全球血压波动时维持恒定血流量的先天能力是一个被称为自我调节的严格控制过程。这依赖于血管平滑肌细胞(SMCs)中的负反馈机制,其中肌浆网(SR)上的ryanodine受体(RyRs)释放的钙火花激活质膜(PM)上的大电导钙活化钾(BK)通道。有效激活需要ryr和BK通道驻留在彼此的~ 20nm内。这种纳米级接近的破坏会损害BK通道的激活,损害慢性高血压期间的血管舒张和血流调节。方法为了研究RyR-BK的空间耦合,我们将利用DNA-PAINT超分辨率显微镜对野生型(C57)、正常型(BPN/3)和高血压型(BPH/2)小鼠分离的SMCs进行成像。共聚焦显微镜将用于量化钙火花活性和每个细胞的火花位点数量,电子显微镜(EM)将在超微结构水平上评估SR- PM接触位点。将使用多光子显微镜在有颅窗的小鼠中测量体内脑血流量(CBF),并通过CO₂挑战评估血管舒张。结果在C57小鼠中,DNA-PAINT显示约40%的ryr位于BK通道30nm内,约90%位于100nm内,表明空间组织紧密。钙成像显示,每个分离的SMC平均有~ 2个钙火花位点,表明功能偶联位点数量有限,初步EM结果证实健康SMC中SR-PM偶联稀疏。这些发现为RyR-BK在健康中的功能性偶联建立了基线。在我们之前的工作中(Taylor et al., 2023),与BPN/3对照相比,BPH/2小鼠表现出CBF减少,BK通道活性受损,RyR-BK偶联位点明显减少,表明慢性高血压期间存在空间解耦。目前的实验正在BPH/2小鼠中使用相同的成像模式扩展这些分析,以进一步评估纳米级变化和功能修饰。这些结果表明,RyR-BK耦合在健康的SMCs中是稀疏的和空间精确的,纳米尺度的组织对于适当的动脉直径控制是必不可少的。慢性高血压破坏了这种安排,导致自我调节受损。了解这种耦合何时以及如何丢失有助于确定新的治疗策略,以恢复脑血管功能和防止认知能力下降。
{"title":"Disruption of ryanodine receptor to BK channel nanodomains in cerebral arteries may underlie hypertension-associated cognitive decline","authors":"Harry Pritchard , Anna Gray , Adam Greenstein , Stuart Allan , Ingo Schiessl , Alexander Clowsley , Christian Soeller , Thea Danby","doi":"10.1016/j.cccb.2025.100498","DOIUrl":"10.1016/j.cccb.2025.100498","url":null,"abstract":"<div><h3>Introduction</h3><div>The innate ability of cerebral resistance vessels to maintain constant blood flow during fluctuations in global blood pressures is a tightly controlled process known as autoregulation. This relies on a negative feedback mechanism in vascular smooth muscle cells (SMCs) where calcium sparks released from ryanodine receptors (RyRs) on the sarcoplasmic reticulum (SR) activate large-conductance calcium-activated potassium (BK) channels on the plasma membrane (PM). Efficient activation requires RyRs and BK channels to reside within ∼20nm of each other. Disruption of this nanoscale proximity impairs BK channel activation, compromising vasodilation and blood flow regulation seen during chronic hypertension.</div></div><div><h3>Methods</h3><div>To investigate RyR-BK spatial coupling, we will utilise DNA-PAINT super- resolution microscopy to image isolated SMCs from wild-type (C57), normotensive (BPN/3), and hypertensive (BPH/2) mice. Confocal microscopy will be used to quantify calcium spark activity and the number of spark sites per cell and electron microscopy (EM) will assess SR- PM contact sites at the ultrastructural level. In-vivo cerebral blood flow (CBF) will be measured using multi-photon microscopy in mice with cranial windows, with vasodilation assessed via CO₂ challenge.</div></div><div><h3>Results</h3><div>In C57 mice, DNA-PAINT revealed that ∼40% of RyRs were located within 30nm of BK channels, with ∼90% within 100nm, suggesting tight spatial organisation. Calcium imaging showed an average of ∼2 calcium spark sites per isolated SMC, indicating a limited number of functional coupling sites where preliminary EM findings confirmed sparse SR-PM coupling in healthy SMCs. These findings establish a baseline for functional RyR-BK coupling in health. In our previous work (Taylor et al., 2023), BPH/2 mice showed reduced CBF, impaired BK channel activity, and significantly fewer RyR-BK coupling sites compared to BPN/3 controls, indicating a spatial uncoupling during chronic hypertension. Current experiments are extending these analyses in BPH/2 mice using the same imaging modalities to further assess nanoscale changes and functional modifications.</div></div><div><h3>Conclusions</h3><div>These results suggest RyR-BK coupling is sparse and spatially precise in healthy SMCs, with nanoscale organisation being essential for proper arterial diameter control. Chronic hypertension disrupts this arrangement contributing to impaired autoregulation. Understanding when and how this coupling is lost could help identify new therapeutic strategies to restore cerebrovascular function and prevent cognitive decline.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100498"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100422
Roberto Duarte Coello , Maria del C. Valdés Hernández , Nina M Rzechorzek , Michael Thrippleton , Joanna M. Wardlaw
Introduction
Perivascular spaces (PVS) in the brain are fluid-filled structures which, when enlarged, become visible on MRI scans. They are believed to play a role in clearing brain fluids. However, daily variations in the size of enlarged PVS have not been thoroughly investigated. If such variations are significant, it may be important to standardise the time of image acquisition or adjust for these changes in PVS analyses.
Methods
We used MRI scans from the Circadian Brain Temperature Study (CiBraT), which consists of healthy volunteers scanned three times in a single day: 9am, 4pm and 11pm.
For this analysis, we included only participants who completed all three scans (N=38). The Basal Ganglia and the Centrum Semiovale regions were analysed. We normalised the T1- and T2-weighted input images. PVS were segmented by thresholding the output of the vesselness filter. We removed outliers based on volume and contrast. We also tested a refinement step based on image intensity for each PVS. We measure: total PVS volume and count, and the mean length, diameter, and volume of individual PVS using a curve approximation (Bezier). Repeated-measures (RM) ANOVA was used to assess whether these measurements varied significantly throughout the day. Analyses were performed separately for T1- and T2-weighted images, using both Frangi and RORPO filters, and with or without the refinement step.
Results
There were no significant differences in any of the PVS measurements across T1- and T2-weighted scans, for the RORPO filter or whether PVS refinement was applied or not. However, refining the PVS segmentation improved the measurement consistency for both filters. RM-ANOVA showed potential differences for some of the Frangi measurements. We noted visually that longer PVS structures were fragmented, which led to an increased count and a decrease in mean individual length and size between scans, which could explain these results.
Conclusions
Our results suggest that PVS volume, count, and morphology in healthy volunteers do not change significantly over the course of the day in brain MRI. Post- processing of PVS segmentations can improve the consistency of these measurements. In terms of morphology and count, the RORPO filter provides more consistent results than the Frangi filter.
{"title":"Enlarged Perivascular Spaces changes during the day in Healthy Volunteers","authors":"Roberto Duarte Coello , Maria del C. Valdés Hernández , Nina M Rzechorzek , Michael Thrippleton , Joanna M. Wardlaw","doi":"10.1016/j.cccb.2025.100422","DOIUrl":"10.1016/j.cccb.2025.100422","url":null,"abstract":"<div><h3>Introduction</h3><div>Perivascular spaces (PVS) in the brain are fluid-filled structures which, when enlarged, become visible on MRI scans. They are believed to play a role in clearing brain fluids. However, daily variations in the size of enlarged PVS have not been thoroughly investigated. If such variations are significant, it may be important to standardise the time of image acquisition or adjust for these changes in PVS analyses.</div></div><div><h3>Methods</h3><div>We used MRI scans from the Circadian Brain Temperature Study (CiBraT), which consists of healthy volunteers scanned three times in a single day: 9am, 4pm and 11pm.</div><div>For this analysis, we included only participants who completed all three scans (N=38). The Basal Ganglia and the Centrum Semiovale regions were analysed. We normalised the T1- and T2-weighted input images. PVS were segmented by thresholding the output of the vesselness filter. We removed outliers based on volume and contrast. We also tested a refinement step based on image intensity for each PVS. We measure: total PVS volume and count, and the mean length, diameter, and volume of individual PVS using a curve approximation (Bezier). Repeated-measures (RM) ANOVA was used to assess whether these measurements varied significantly throughout the day. Analyses were performed separately for T1- and T2-weighted images, using both Frangi and RORPO filters, and with or without the refinement step.</div></div><div><h3>Results</h3><div>There were no significant differences in any of the PVS measurements across T1- and T2-weighted scans, for the RORPO filter or whether PVS refinement was applied or not. However, refining the PVS segmentation improved the measurement consistency for both filters. RM-ANOVA showed potential differences for some of the Frangi measurements. We noted visually that longer PVS structures were fragmented, which led to an increased count and a decrease in mean individual length and size between scans, which could explain these results.</div></div><div><h3>Conclusions</h3><div>Our results suggest that PVS volume, count, and morphology in healthy volunteers do not change significantly over the course of the day in brain MRI. Post- processing of PVS segmentations can improve the consistency of these measurements. In terms of morphology and count, the RORPO filter provides more consistent results than the Frangi filter.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100422"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100414
Francesco Gill, Dexter Penn, Oliver Warrington, Alastair Webb
Introduction
Cerebral hypoperfusion and increased pulsatility are associated with cerebral small vessel disease and vascular dementia (VaD). However, our systematic review identified no studies assessing the effects of pacemaker settings on these parameters or the risk of VaD after pacemaker implantation. We therefore determined dementia risk in people undergoing pacemaker implantation in the large UK Biobank cohort.
Methods
In >500,000 participants in the UK Biobank cohort, we determined the absolute incidence of all-cause dementia and VaD in participants with pacemakers at recruitment or undergoing pacemaker implantation during follow-up, stratified by age and gender. To account for baseline age differences, an age and sex matched control group were derived for each individual receiving a pacemaker during follow-up (5:1 case - control ratio).
Predictors of pacemaker implantation were determined by binomial logistic regression. Dementia risk was determined by Kaplan – Meier curves and Cox’ s proportional hazards, unadjusted and adjusted for cardiovascular risk factors and predictors of pacemaker implantation including HF and MI.
Results
Of 502,128 participants (median follow-up= 13.6 years), 11,811 had pacemakers, with a mean age of 62 years. Absolute incidence of all-cause dementia was greatest in 10, 258 people after pacemaker implantation during the study (654/100,000 person years), then in people with pacemakers at baseline (448/100,000 person years) and lowest in non- paced people (141/100,000 person years, p<0.0001), with similar differences for VaD (249 vs 154 vs 30 /100,000 person years, p<0.0001). Compared to those that were never paced, all-cause dementia risk was significantly higher in people paced at baseline (HR= 3.42, 2.76 - 4.24 95%CI, p= <0.05), or after pacemaker implantation in the age and sex- matched dataset (HR = 1.47, 1.30 - 1.67 95% CI), even after adjustment (baseline HR = 1.32; during HR= 1.37), with consistent effects for VaD (adjusted: baseline HR= 1.77; during HR= 1.38).
Conclusions
In the UKB, participants with pacemakers had a high risk of dementia, identifying a key target for future interventions. Future studies should investigate how to optimise pacemaker settings to improve cerebral haemodynamics, and whether this reduces the subsequent risk of cognitive decline.
{"title":"Effects of pacemaker implantation on the risk of vascular cognitive decline","authors":"Francesco Gill, Dexter Penn, Oliver Warrington, Alastair Webb","doi":"10.1016/j.cccb.2025.100414","DOIUrl":"10.1016/j.cccb.2025.100414","url":null,"abstract":"<div><h3>Introduction</h3><div>Cerebral hypoperfusion and increased pulsatility are associated with cerebral small vessel disease and vascular dementia (VaD). However, our systematic review identified no studies assessing the effects of pacemaker settings on these parameters or the risk of VaD after pacemaker implantation. We therefore determined dementia risk in people undergoing pacemaker implantation in the large UK Biobank cohort.</div></div><div><h3>Methods</h3><div>In >500,000 participants in the UK Biobank cohort, we determined the absolute incidence of all-cause dementia and VaD in participants with pacemakers at recruitment or undergoing pacemaker implantation during follow-up, stratified by age and gender. To account for baseline age differences, an age and sex matched control group were derived for each individual receiving a pacemaker during follow-up (5:1 case - control ratio).</div><div>Predictors of pacemaker implantation were determined by binomial logistic regression. Dementia risk was determined by Kaplan – Meier curves and Cox’ s proportional hazards, unadjusted and adjusted for cardiovascular risk factors and predictors of pacemaker implantation including HF and MI.</div></div><div><h3>Results</h3><div>Of 502,128 participants (median follow-up= 13.6 years), 11,811 had pacemakers, with a mean age of 62 years. Absolute incidence of all-cause dementia was greatest in 10, 258 people after pacemaker implantation during the study (654/100,000 person years), then in people with pacemakers at baseline (448/100,000 person years) and lowest in non- paced people (141/100,000 person years, p<0.0001), with similar differences for VaD (249 vs 154 vs 30 /100,000 person years, p<0.0001). Compared to those that were never paced, all-cause dementia risk was significantly higher in people paced at baseline (HR= 3.42, 2.76 - 4.24 95%CI, p= <0.05), or after pacemaker implantation in the age and sex- matched dataset (HR = 1.47, 1.30 - 1.67 95% CI), even after adjustment (baseline HR = 1.32; during HR= 1.37), with consistent effects for VaD (adjusted: baseline HR= 1.77; during HR= 1.38).</div></div><div><h3>Conclusions</h3><div>In the UKB, participants with pacemakers had a high risk of dementia, identifying a key target for future interventions. Future studies should investigate how to optimise pacemaker settings to improve cerebral haemodynamics, and whether this reduces the subsequent risk of cognitive decline.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100414"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-14DOI: 10.1016/j.cccb.2025.100420
Zaylea Kua, Ruijia Tian, Boon Thye Thomas Yeo, Yanhong Dong, Richard Henson, Kamen Tsvetanov
Introduction
Brain-Age Gap (BAG), which quantifies deviations between an individual’s predicted brain age and chronological age, has emerged as a novel tool for investigating risk factors on brain health. White matter and cognitive decline are affected by vascular risk factors (VRFs), but it is unclear to what extent white matter (WM) disruptions contribute independently of gray matter (GM) differences. This study hypothesized that the effect of VRFs on cognitive abilities in healthy adults would be mediated by WM-BAG, potentially independently of GM-BAG.
Methods
This cross-sectional study was based on the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) lifespan healthy adult cohort (age 18-88 years). WM-BAG was estimated from 8 diffusion metrics x 48 ROIs using a Least Absolute Shrinkage and Selection Operator regression model while GM-BAG was estimated from 4 morphometric measures x 148 ROIs using an Elastic Net regression model; both were bias-corrected. VRF status (binary) was defined by presence of ≥1: current smoking, hypertension, hyperlipidemia, or BMI ≥ 30 kg/m². Cognitive outcomes were processing speed from a speeded key-press task, and fluid intelligence from the Cattell test. Mediation analysis of the direct VRF->Cognition path by an indirect path via WM-BAG was estimated using Python (pingouin v0.5.3), after controlling for age, sex, years of education and GM-BAG.
Results
Of 503 participants in the final analytical sample, 38.4% were VRF-positive. Presence of VRF predicted higher WM-BAG (β = 1.29, SE = 0.55, p = 0.019). Following adjustment of age, sex, and education, WM-BAG fully mediated the association between VRF and processing speed (23.0% mediation proportion, p = 0.013) while a suppression effect was observed for fluid intelligence (p = 0.008); see Figure 1. Following additional adjustment for GM-BAG, the indirect effect remained significant for fluid intelligence (p = 0.039), though that for processing speed was attenuated. Sex‐stratified analyses revealed that WM-mediated vascular effects on cognition were more pronounced in females than in males.
Conclusions
Our findings suggest that behaviorally relevant white matter disruption, captured by WM-BAG, is especially sensitive to vascular risk and may serve as an early biomarker of cerebrovascular contributions to cognitive decline, with potential sex-specific vulnerabilities that warrant targeted intervention.
{"title":"White Matter Brain Age Gap Independently Mediates Vascular Risk and Cognitive Decline Beyond Grey Matter Age","authors":"Zaylea Kua, Ruijia Tian, Boon Thye Thomas Yeo, Yanhong Dong, Richard Henson, Kamen Tsvetanov","doi":"10.1016/j.cccb.2025.100420","DOIUrl":"10.1016/j.cccb.2025.100420","url":null,"abstract":"<div><h3>Introduction</h3><div>Brain-Age Gap (BAG), which quantifies deviations between an individual’s predicted brain age and chronological age, has emerged as a novel tool for investigating risk factors on brain health. White matter and cognitive decline are affected by vascular risk factors (VRFs), but it is unclear to what extent white matter (WM) disruptions contribute independently of gray matter (GM) differences. This study hypothesized that the effect of VRFs on cognitive abilities in healthy adults would be mediated by WM-BAG, potentially independently of GM-BAG.</div></div><div><h3>Methods</h3><div>This cross-sectional study was based on the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) lifespan healthy adult cohort (age 18-88 years). WM-BAG was estimated from 8 diffusion metrics x 48 ROIs using a Least Absolute Shrinkage and Selection Operator regression model while GM-BAG was estimated from 4 morphometric measures x 148 ROIs using an Elastic Net regression model; both were bias-corrected. VRF status (binary) was defined by presence of ≥1: current smoking, hypertension, hyperlipidemia, or BMI ≥ 30 kg/m². Cognitive outcomes were processing speed from a speeded key-press task, and fluid intelligence from the Cattell test. Mediation analysis of the direct VRF->Cognition path by an indirect path via WM-BAG was estimated using Python (pingouin v0.5.3), after controlling for age, sex, years of education and GM-BAG.</div></div><div><h3>Results</h3><div>Of 503 participants in the final analytical sample, 38.4% were VRF-positive. Presence of VRF predicted higher WM-BAG (β = 1.29, SE = 0.55, p = 0.019). Following adjustment of age, sex, and education, WM-BAG fully mediated the association between VRF and processing speed (23.0% mediation proportion, p = 0.013) while a suppression effect was observed for fluid intelligence (p = 0.008); see Figure 1. Following additional adjustment for GM-BAG, the indirect effect remained significant for fluid intelligence (p = 0.039), though that for processing speed was attenuated. Sex‐stratified analyses revealed that WM-mediated vascular effects on cognition were more pronounced in females than in males.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that behaviorally relevant white matter disruption, captured by WM-BAG, is especially sensitive to vascular risk and may serve as an early biomarker of cerebrovascular contributions to cognitive decline, with potential sex-specific vulnerabilities that warrant targeted intervention.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"9 ","pages":"Article 100420"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145796914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}